804551-71-1 Usage
General Description
CHIR-258 is a chemical compound belonging to the class of protein kinase inhibitors. It is used in biological research to study the role of specific kinases in cellular processes. CHIR-258 has been shown to selectively inhibit a range of protein kinases such as Lck, Lck-SH2, and Lck-SH3, and has potential therapeutic applications in the treatment of diseases such as cancer and inflammatory disorders. CHIR-258 has demonstrated promising results in preclinical studies and may represent a novel and effective approach for targeting specific signaling pathways in disease states. Further research is needed to fully understand the potential of CHIR-258 in therapeutic and diagnostic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 804551-71-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,0,4,5,5 and 1 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 804551-71:
(8*8)+(7*0)+(6*4)+(5*5)+(4*5)+(3*1)+(2*7)+(1*1)=151
151 % 10 = 1
So 804551-71-1 is a valid CAS Registry Number.
InChI:InChI=1/C21H21FN6O.C3H6O3.H2O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;1-2(4)3(5)6;/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2,4H,1H3,(H,5,6);1H2
804551-71-1Relevant articles and documents
Method for preparing dovitinib intermediate with microchannel reaction device
-
Paragraph 0032; 0045-0048-0051-0052; 0055-0056; 0059, (2018/10/19)
The invention discloses a method for preparing a dovitinib intermediate with a microchannel reaction device. The method comprises the following steps: (1) dissolving hydrochloric acid in ethanol to form a mixed solution, and enabling the mixed solution an
TREATMENT OF MELANOMA
-
Page/Page column 35-36, (2008/12/07)
Methods of treating melanoma include administering a compound of Structure (I), a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The comp
The chemical development of CHIR-258
Zhu, Shuguang,Harwood, Eric,Cai, Shaopei,Shang, Xiao,Galvin, Gabriel,Jin, Li,Yeung, Arthur,Diaz, Brian,Zheng, Minna,Ryckman, David
, p. 584 - 592 (2007/10/03)
This paper is a case history of the early stage chemical development of CHIR-258 (4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- 2(1H)-quinolinone, DL-lactate salt), a vascular endothelial growth factor (VEGF) kinase inhibitor for t
